Clinical trials: NASH (Nonalcoholic Steatohepatitis)
Non-Alcoholic Fatty Liver Disease, Fat Soluble Vitamin Deficiencies and Disorders
Study on the Correlation Between Fat Soluble Vitamins and Non-alcoholic Fatty Liver Disease
Excessive or insufficient levels of vitamins in the body can affect health. With the prevalence of obesity and MetS, NAFLD has become the leading cause of chronic liver disease and abnormal liver biochemical indicators in health…
- Trial name
- NCT06512701
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Type 2 Diabetes Mellitus With Complication
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
Type 2 diabetes mellitus (T2DM) is always accompanied with nonalcoholic fatty liver disease (NAFLD).This prospective, randomized controlled intervention study was designed to reveal the potential clinical application and…
- Trial name
- NCT05422092
- Testing
- Canagliflozin, Pioglitazone
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD: The LiverSeek Programme
LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Liver Fibrosis, Non-alcoholic Fatty Liver Disease NAFLD, Type 2 Diabetes Mellitus
- Trial name
- LiverSeek (NCT07658755)
- Where
- Spain
- Volunteers
- 3,000 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Non-alcoholic Steatohepatitis, Fatty Liver
Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH) occurs in 2-3% of the US population and carries a 15-20% chance of progression to cirrhosis. It is closely associated with obesity, hyperlipidemia and insulin resistance.
- Trial name
- NCT00681408
- Testing
- Omega 3 Fish Oil supplements
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Virginia
Metabolic Dysfunction-associated Fatty Liver Disease
The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods
This is a case-control study that aims to build a predictive model for MAFLD based on machine learning.
- Trial name
- NCT06061640
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
Schizophrenia, Psychosis
Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis
This study aims to evaluate, at long-term, the occurrence of liver disease and cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective psychosis.
- Conditions
- Schizophrenia, Psychosis, Metabolic Syndrome
- Trial name
- NCT03481465
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Marques de Valdecilla
Non-Alcoholic Fatty Liver Disease, Low Birth Weight
Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
The investigators recently demonstrated a increase in liver fat in early middle-aged LBW compared to normal birth weight (NBW) men, and 20% of the LBW - but none of the normal birth weight (NBW) - men had previously unknown…
- Trial name
- NCT05890365
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Steno Diabetes Center Copenhagen
Metabolic Dysfunction-associated Steatotic Liver Disease
Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of liver disease worldwide. The condition is defined by fat accumulation exceeding 5% of liver weight not explained by at-risk alcohol…
- Trial name
- MPM (NCT06495333)
- Where
- Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Fundacion de Investigacion Science and Education
NASH, MASH
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.
- Conditions
- NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
- Trial name
- HERALD (NCT06342947)
- Testing
- ALG-055009
- Where
- 40 sites in United States
- Volunteers
- 102 people
- Sponsor
- Aligos Therapeutics
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH).
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT05877547
- Testing
- Efinopegdutide, Semaglutide
- Where
- 175 sites in United States, Austria and 24 more
- Volunteers
- 381 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatic Steatosis, NAFLD
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
Participants 13-18 years of age with extra fat stored in the liver will be randomly assigned to a protein supplement or placebo "fake supplement" for 2 months to see if the participants who get the protein supplement have less…
- Conditions
- Hepatic Steatosis, NAFLD, Adolescent Obesity
- Trial name
- AMINOS (NCT05935826)
- Testing
- Essential Amino Acid Supplement by Amino Co
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Colorado, Denver
Obstructive Sleep Apnea, Non-alcoholic Fatty Liver
Free Walking Exercise in Obstructive Sleep Apnea Patients With Non-alcoholic Fatty Liver
Research evaluating the impact of continuous positive airway pressure (CPAP) \& walking exercise on fatigue severity, liver enzymes and sleeping quality in patients with non-alcoholic fatty liver disease who also have obstructive…
- Trial name
- NCT06508190
- Testing
- continuous positive airway pressure, free walking exercise and continuous positive airway pressure
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ahram Canadian University
Fatty Liver
Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Utilizing Ultrasound and Percutaneous Liver Biopsy
Prospective determination of the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)in a primary care setting using ultrasound and percutaneous liver biopsy.
- Trial name
- NCT01100398
- Testing
- possible liver biopsy and serum collection
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Brooke Army Medical Center
Non-Alcoholic Fatty Liver Disease
Effect of Molecular Hydrogen in Patients With NAFLD
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective…
- Trial name
- EMoHyNAFLD (NCT05325398)
- Testing
- HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
- Where
- Slovakia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Comenius University
Effects of Bacillus Coagulans TCI711 Supplementation on Liver and Gut Microbiota Function in Non-alcoholic Fatty Liver Disease Patients
Effects of Bacillus Coagulans on Liver and Gut Microbiota Function in NAFLD
According to the 2018 statistics of the American Association of Liver Diseases, about 25% of the world's population has non-alcoholic fatty liver disease, and about 10 to 20% of patients with simple fatty liver will develop…
- Trial name
- NCT05635474
- Testing
- Bacillus Coagulans
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University
Non-Alcoholic Fatty Liver Disease, Liver Fat
Diet, Immunometabolism and Non-alcoholic Fatty Liver Disease
This study will assess the impact of 8-hour time restricted eating (8 hours of eating, 16 hours fasting) combined with a Mediterranean diet on metabolism and inflammation in adults with non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Fat, Obesity, Inflammation
- Trial name
- NCT05968378
- Testing
- Standard healthy eating advice, eTRE plus Mediterranean diet
- Where
- Ireland
- Volunteers
- 60 people
- Sponsor
- University College Dublin
Liver Diseases
Metformin in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to examine the effect of metformin on biochemical and histological findings in NAFLD patients with insulin resistance syndrome.
- Trial name
- NCT00247117
- Testing
- Metformin
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Kaplan Medical Center
NAFLD, PCOS
Bicalutamide Therapy in Young Women With NAFLD and PCOS
Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years.
- Trial name
- NCT05979389
- Testing
- Bicalutamide 50 mg
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Nonalcoholic Steatohepatitis, Liver Fibrosis
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem.
- Trial name
- NCT05526144
- Testing
- Synthroid
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.